Comparative Pharmacology
Head-to-head clinical analysis: DELFLEX W DEXTROSE 4 25 IN PLASTIC CONTAINER versus DELFLEX LM W DEXTROSE 2 5 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DELFLEX W DEXTROSE 4 25 IN PLASTIC CONTAINER versus DELFLEX LM W DEXTROSE 2 5 IN PLASTIC CONTAINER.
DELFLEX W/ DEXTROSE 4.25% IN PLASTIC CONTAINER vs DELFLEX-LM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER
Head-to-head clinical comparison of therapeutic indices and safety profiles.
Peritoneal dialysis solution with dextrose as osmotic agent; removes solutes and water across peritoneal membrane via diffusion and ultrafiltration.
Delflex-LM with Dextrose 2.5% is a peritoneal dialysis solution. Dextrose provides osmotic gradient for ultrafiltration; lactate (LM) is a bicarbonate precursor that buffers metabolic acidosis. The solution replaces fluid and electrolytes while removing waste products via diffusion and convection across the peritoneal membrane.
Continuous ambulatory peritoneal dialysis (CAPD)Continuous cycling peritoneal dialysis (CCPD)Acute kidney injury requiring peritoneal dialysis
Continuous ambulatory peritoneal dialysis (CAPD)Continuous cycling peritoneal dialysis (CCPD)
Intraperitoneal administration: 2 L per exchange, typically 4 exchanges daily (continuous ambulatory peritoneal dialysis). Dextrose 4.25% solution used for ultrafiltration. Dose adjusted based on body size and fluid status.
Intraperitoneal administration: 2 liters of 2.5% dextrose solution per exchange, typically 4 exchanges daily (8 liters total). Adjust volume and frequency based on patient's dry weight, residual renal function, and peritoneal membrane transport characteristics.
None Documented
None Documented
Not applicable as a drug; dextrose is rapidly metabolized; plasma half-life of glucose ~1.5-2 hours; continuous reabsorption in dialysis prevents accumulation.
Dextrose: ~1-2 hours for plasma glucose levels; lactate: ~30-60 minutes for conversion to bicarbonate.
Dextrose absorbed systemically and metabolized via glycolysis; lactate buffer converted to bicarbonate in liver.
Dextrose is metabolized via glycolysis and oxidative phosphorylation; lactate is converted to bicarbonate in the liver and kidneys via lactate dehydrogenase.
Peritoneal dialysis; effectively removed via peritoneal membrane during dialysis exchanges; systemic absorption of dextrose minimal; elimination primarily through dialysate outflow; renal excretion negligible in anuria.
Peritoneal dialysis fluid components: dextrose is metabolized to CO2 and water; lactate is converted to bicarbonate in liver; electrolytes are variably reabsorbed. ~70% of administered dextrose is absorbed; elimination primarily via metabolic pathways.
Not applicable; dextrose does not bind to plasma proteins.
Dextrose: negligible; lactate: <10% bound to albumin.
Not applicable; dextrose distributes throughout total body water (~0.55 L/kg); dialysate instilled volume is ~2 L per exchange.
Dextrose: Vd ~0.25 L/kg (total body water); lactate: Vd ~0.5 L/kg.
100% via intraperitoneal route as dialysate; dextrose absorbed systemically at ~10-20 g per exchange depending on dwell time and concentration.
Not applicable: intraperitoneal administration bypasses gastrointestinal absorption; dextrose absorption ~70-80% of administered dose over dwell time.
No dose adjustment needed for impaired kidney function as drug is administered intraperitoneally for dialysis; however, monitor serum electrolytes and fluid balance.
Dosing is titrated based on residual renal function and peritoneal dialysis adequacy. For patients with GFR <10 mL/min, standard regimen is used. Adjust exchange volume and number to achieve weekly Kt/V ≥1.7.
No specific dose adjustment recommended. Caution in severe hepatic impairment due to potential lactic acidosis with dextrose-containing solutions.
No specific Child-Pugh based dose adjustments; monitor for glucose intolerance and fluid overload. In severe hepatic impairment, consider reduced dextrose concentration to avoid hyperglycemia.
Intraperitoneal: 30-40 mL/kg per exchange, up to 1 L per exchange depending on body size; frequency as needed for dialysis. Dextrose concentration tailored to ultrafiltration needs.
Initial exchange volume: 10-20 mL/kg per exchange, up to 1100 mL/m² body surface area per exchange. Number of exchanges: 4-5 per day. Titrate based on ultrafiltration and metabolic control.
Start with lower volumes (e.g., 1.5-2 L per exchange) and monitor for fluid overload and glucose intolerance. Use lowest effective dextrose concentration to minimize hyperglycemia.
Start with lower exchange volumes (1.5-2 liters) and monitor for fluid overload and electrolyte imbalances. Adjust dextrose concentration to minimize hyperglycemia. Use same exchange frequency as adults.
Not for intravenous use.
None
["Monitor serum electrolytes, glucose, and fluid balance","Risk of peritonitis with catheter use","Hypokalemia or hyperglycemia possible","Not for IV administration"]
Peritonitis risk; monitor for hyperglycemia, volume overload, hypokalemia, hypomagnesemia, and acidosis; strict aseptic technique; not for IV use; monitor serum electrolytes and glucose.
["Pre-existing severe hyperglycemia","Hypersensitivity to any component","Documented loss of peritoneal function","Abdominal conditions compromising dialysis (e.g., recent surgery, adhesions)"]
Pre-existing severe lactic acidosis, hypersensitivity to any component, documented inability to perform peritoneal dialysis, recent abdominal surgery with prosthetic material, severe abdominal wall infection or burn, pregnancy (relative).
Data Pending Review
Data Pending Review
No specific food interactions. However, dietary restrictions typically include limiting sodium, potassium, phosphorus, and fluid intake as recommended by the nephrologist. Avoid high-potassium foods (e.g., bananas, oranges, tomatoes) and high-phosphorus foods (e.g., dairy, nuts, colas) to prevent electrolyte imbalances. Consult a renal dietitian for personalized meal planning.
No direct dietary interactions with the dialysis solution itself. However, patients on peritoneal dialysis should follow a renal diet: limit sodium, potassium, phosphorus, and fluid intake as advised. Avoid high-phosphorus foods (dairy, nuts, colas) and high-potassium foods (bananas, oranges, potatoes). Use salt substitutes only if recommended, as they may contain potassium. Maintain adequate protein intake unless restricted. Consult a renal dietitian for individualized meal planning.
Delflex w/ Dextrose 4.25% is a peritoneal dialysis solution. No direct fetal risks are expected from the solution itself; however, maternal metabolic disturbances (e.g., hyperglycemia, electrolyte imbalances) could affect the fetus. In the first trimester, uncontrolled diabetes may increase the risk of congenital anomalies. In the second and third trimesters, maternal hyperglycemia may lead to fetal macrosomia, neonatal hypoglycemia, and polyhydramnios.
Peritoneal dialysis solutions are generally considered low risk due to minimal systemic absorption. No specific teratogenic effects reported; however, electrolyte imbalances or metabolic disturbances from improper use could theoretically affect fetal development. Use only if clearly indicated.
Dextrose and electrolytes from the solution may equilibrate with maternal plasma. Excretion into breast milk is likely minimal and not clinically significant. The M/P ratio is not established; however, the risk to the nursing infant is considered low. Monitoring infant for signs of electrolyte imbalance or hyperglycemia is prudent if maternal serum concentrations are elevated.
No data on excretion into breast milk. Clinically insignificant systemic absorption suggests minimal risk to nursing infant. Caution with additives (e.g., dextrose, electrolytes). M/P ratio not available.
Pregnancy increases plasma volume and glomerular filtration rate, potentially altering pharmacokinetics of components. No specific dose adjustments for Delflex w/ Dextrose 4.25% are established; however, frequent monitoring of maternal glucose and electrolytes is advised to adjust dialysis prescription as needed to maintain metabolic control.
No standard dose adjustments required due to minimal systemic absorption. However, increased maternal plasma volume and altered electrolyte needs may necessitate adjustment of dialysis prescription (e.g., dextrose concentration, volume) to avoid hypoglycemia, hyperglycemia, or electrolyte disturbances. Individualize based on maternal and fetal status.
Category C
Category C
DELFLEX W/ DEXTROSE 4.25% is a peritoneal dialysis solution used in continuous ambulatory peritoneal dialysis (CAPD) or automated peritoneal dialysis (APD). Monitor for signs of peritonitis, such as cloudy effluent, abdominal pain, and fever. Ensure strict aseptic technique during exchange to prevent infection. The 4.25% dextrose concentration is hypertonic and used for ultrafiltration in fluid overload. Check electrolyte levels regularly, especially potassium and magnesium, as dialysis can alter serum levels. Warm the solution to body temperature before use to improve comfort and dialysis efficiency.
DELFLEX-LM W/ DEXTROSE 2.5% is a peritoneal dialysis solution with low magnesium (0.5 mEq/L) and low calcium (2.5 mEq/L), suitable for patients with hypercalcemia or to reduce calcium load. Monitor serum electrolytes, especially potassium and magnesium, during therapy. Do not use if solution is discolored or contains particulate matter. Warm solution to body temperature before use to reduce discomfort. Use aseptic technique to prevent peritonitis. Verify correct dextrose concentration to avoid unintended hyperglycemia.
Wash hands thoroughly before handling the dialysis solution or performing exchanges.Use a clean, dry area for all exchanges and keep the catheter site clean and dry.Inspect the solution bag for cloudiness, leaks, or particulate matter before use; do not use if any are present.Do not reuse or refrigerate the solution; store at room temperature and protect from light.Report any signs of infection such as redness, swelling, or drainage at the catheter site, or cloudy effluent immediately.Follow your prescribed exchange schedule exactly to maintain proper fluid and waste removal.
Inspect the bag for any leaks or cloudy solution before use; do not use if damaged or discolored.Warm the solution to body temperature (approximately 37°C) by placing the bag in a warm water bath—do not microwave.Wash hands thoroughly and use sterile technique when connecting and disconnecting the dialysis lines.Report any signs of infection such as fever, abdominal pain, or cloudy drainage fluid immediately.Monitor blood glucose regularly as the dextrose in the solution can raise blood sugar.Adhere to the prescribed dialysis schedule and do not skip or extend exchanges without medical advice.